z-logo
Premium
Prognostic importance of cognitive impairment in chronic heart failure patients: Does specialist management make a difference?
Author(s) -
McLennan Skye N.,
Pearson Sue A.,
Cameron Janette,
Stewart Simon
Publication year - 2006
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2005.11.013
Subject(s) - medicine , heart failure , cognitive impairment , cardiology , intensive care medicine , cognition , psychiatry , disease
Background: Cognitive impairment is common among chronic heart failure (CHF) patients. Aims: To determine the prognostic significance of cognitive impairment in patients participating in a randomized study of a CHF management program (CHF‐MP). Methods CHF patients were randomized to a CHF‐MP ( n =100) or usual care ( n =100). Baseline cognition was assessed using the Mini Mental Status Examination (MMSE). Five‐year all‐cause mortality, and combined death‐or‐readmission, were compared on the basis of the presence (MMSE 19–26) or absence (MMSE >26) of cognitive impairment. Results: 27 patients (13.5%) had cognitive impairment and, on an adjusted basis, were more likely to die (96.3% versus 68.2%. RR 2.19, 95% CI 1.41 to 3.39: P <0.001) and/or experience an unplanned hospitalization (100% versus 94%. RR 1.44, 95% CI 1.06 to 1.95: P =0.019). Cognitively impaired patients had a similar (non‐significant) adjusted risk of death‐or‐readmission in both the CHF‐MP (RR 1.40, 95% CI 0.63 to 3.11: P =0.403) and in usual care (RR 1.38, 95% CI 0.75 to 2.53: P =0.305). In the usual care cohort, cognitive impairment was associated with a greater (non‐significant), adjusted risk of death (RR 1.61, 95% CI 1.10 to 4.92: P =0.122). In the CHF‐MP, adjusted risk of death was significantly higher for cognitively impaired patients (RR 2.33, 95% CI 1.10 to 4.92: P =0.027). Conclusion These data suggest that “mild” cognitive impairment is of prognostic importance in CHF: even when a CHF‐MP has been applied.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom